RECRUIT-TandAbs^®: harnessing the immune system to kill cancer cells

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature314(6012),628–631 (1985).
  Medline CASGoogle Scholar
• 2  Karpovsky B, Titus JA, Stephany DA, Segal DM. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Exp. Med.160(6),1686–1701 (1984).
  Medline CASGoogle Scholar
• 3  Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature316(6026),354–356 (1985).
  Medline CASGoogle Scholar
• 4  Cochran JR. Engineered proteins pull double duty. Sci. Transl Med.2(17),17ps5 (2010).
  MedlineGoogle Scholar
• 5  Leonard JP, Schuster SJ, Emmanouilides C et al. Durable complete responses from therapy with combined epratuzumab and rituximab. Final results from an international multicenter, Phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer113(10),2714–2723 (2008).
  Medline CASGoogle Scholar
• 6  Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res.69(12),4941–4944 (2009).
  Medline CASGoogle Scholar
• 7  Johnson S, Burke S, Huang L et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol.399(3),436–449 (2010).
  Medline CASGoogle Scholar
• 8  Kipriyanov SM, Moldenhauer G, Schuhmacher J et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol.293(1),41–56 (1999).▪▪ Describes the design, expression, biophysical properties and activity of CD3 × CD19-specific tandem diabodies (TandAbs®).
  Medline CASGoogle Scholar
• 9  Bostrom J, Yu SF, Kan D et al. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science323(5921),1610–1614 (2009).
  Medline CASGoogle Scholar
• 10  Doppalapudi VR, Huang J, Liu D et al. Chemical generation of bispecific antibodies. Proc. Natl Acad. Sci. USA107(52),22611–22616 (2010).
  Medline CASGoogle Scholar
• 11  Wu C, Ying H, Bose S et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs1(4),339–347 (2009).
  MedlineGoogle Scholar
• 12  Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther.2(1),19–31 (2007).
  MedlineGoogle Scholar
• 13  Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr. Opin Biotechnol.22(6),849–857 (2011).
  Medline CASGoogle Scholar
• 14  Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng. Des. Sel.24(1–2),3–9 (2011).
  Medline CASGoogle Scholar
• 15  Skerra A. Alternative binding proteins: anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J.275(11),2677–2683 (2008).
  Medline CASGoogle Scholar
• 16  Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov. Today13(15–16),695–701 (2008).
  Medline CASGoogle Scholar
• 17  Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr. Opin Mol. Ther.11(1),22–30 (2009).▪▪ Reviews the potential of T-cell engagement for cancer therapy, as well as the clinical proof of concept for such approaches.
  Medline CASGoogle Scholar
• 18  Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs24(2),89–98 (2010).
  Medline CASGoogle Scholar
• 19  Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs1(6),539–547 (2009).▪ Describes recent developments and clinical trial results for bispecific antibodies used in the treatment of cancer.
  MedlineGoogle Scholar
• 20  Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (Removab). J. Cancer2,309–316 (2011).▪ Reviews Triomab® technology, focusing on catumaxomab.
  Medline CASGoogle Scholar
• 21  Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol.155(1),219–225 (1995).
  Medline CASGoogle Scholar
• 22  Chelius D, Ruf P, Gruber P et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs2(3),309–319 (2010).
  MedlineGoogle Scholar
• 23  Zeidler R, Mysliwietz J, Csanady M et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer83(2),261–266 (2000).
  Medline CASGoogle Scholar
• 24  Zeidler R, Reisbach G, Wollenberg B et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol.163(3),1246–1252 (1999).
  Medline CASGoogle Scholar
• 25  Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl Acad. Sci. USA92(15),7021–7025 (1995).
  Medline CASGoogle Scholar
• 26  Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science321(5891),974–977 (2008).
  Medline CASGoogle Scholar
• 27  Topp MS, Kufer P, Gokbuget N et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol.29(18),2493–2498 (2011).▪ Describes the clinical outcome of the CD3 × CD19-targeting bispecific T-cell engager for the treatment of B-cell acute lymphoblastic leukemia.
  Medline CASGoogle Scholar
• 28  Brischwein K, Schlereth B, Guller B et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol.43(8),1129–1143 (2006).
  Medline CASGoogle Scholar
• 29  Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol. Biol.562,177–193 (2009).▪ Details the engineering and expression of TandAbs in Escherichia coli.
  Medline CASGoogle Scholar
• 30  Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA90(14),6444–6448 (1993).
  Medline CASGoogle Scholar
• 31  Kipriyanov SM, Moldenhauer G, Braunagel M et al. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol.330(1),99–111 (2003).
  Medline CASGoogle Scholar
• 32  Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng. Des. Sel.17(4),357–366 (2004).
  Medline CASGoogle Scholar
• 33  Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp. Cell Res.317(9),1278–1285 (2011).
  Medline CASGoogle Scholar
• 34  Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood90(3),1109–1114 (1997).
  Medline CASGoogle Scholar
• 35  Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol.26(11),1789–1796 (2008).
  Medline CASGoogle Scholar
• 36  Treon SP, Hansen M, Branagan AR et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia. J. Clin. Oncol.23(3),474–481 (2005).
  Medline CASGoogle Scholar
• 37  Eichenauer DA, Fuchs M, Borchmann P, Engert A; German Hodgkin Study Group. Hodgkin’s lymphoma: current treatment strategies and novel approaches. Expert Rev. Hematol.1(1),63–73 (2008).
  Medline CASGoogle Scholar
• 38  Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin’s lymphoma. Biochem. Pharmacol.79(11),1544–1552 (2010).
  Medline CASGoogle Scholar
• 39  Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv. Exp. Med. Biol.647,174–185 (2009).
  Medline CASGoogle Scholar
• 40  Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med.363(19),1812–1821 (2010).
  Medline CASGoogle Scholar
• 41  Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313(5795),1960–1964 (2006).
  Medline CASGoogle Scholar
• 42  Wahlin BE, Sander B, Christensson B, Kimby E. CD8⁺ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res.13(2 Pt 1),388–397 (2007).
  Medline CASGoogle Scholar
• 43  Wahlin BE, Sundstrom C, Holte H et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin. Cancer Res.17(12),4136–4144 (2011).
  Medline CASGoogle Scholar
• 44  Gross S, Geldmacher A, Sharav T, Losch F, Walden P. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines. Vaccine27(25–26),3398–3400 (2009).
  Medline CASGoogle Scholar
• 45  Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol. Ther.7(8),1245–1256 (2007).
  Medline CASGoogle Scholar
• 46  Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol.25,267–296 (2007).
  Medline CASGoogle Scholar
• 47  Dave VP. Hierarchical role of CD3 chains in thymocyte development. Immunol. Rev.232(1),22–33 (2009).
  Medline CASGoogle Scholar
• 48  Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol.7(8),622–632 (2007).
  Medline CASGoogle Scholar
• 49  Renders L, Valerius T. Engineered CD3 antibodies for immunosuppression. Clin. Exp. Immunol.133(3),307–309 (2003).
  Medline CASGoogle Scholar
• 50  Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin’s lymphoma. Neth. J. Med.67(8),311–321 (2009).
  Medline CASGoogle Scholar
• 51  Moore PA, Zhang W, Rainey GJ et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood117(17),4542–4551 (2011).
  Medline CASGoogle Scholar
• 52  Cochlovius B, Kipriyanov SM, Stassar MJ et al. Cure of Burkitt’s lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res.60(16),4336–4341 (2000).▪ In vivo proof of concept for a CD19 × CD3-targeting TandAbs.
  Medline CASGoogle Scholar
• 101  National Cancer Institute: Hodgkin Lymphoma.www.cancer.gov/cancertopics/types/hodgkin
  Google Scholar